Showing 1371-1380 of 4848 results for "".
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at
- Almirall S.A. to Aquire Aqua Pharmaceuticalshttps://practicaldermatology.com/news/20131217-almirall_sa_to_aquire_aqua_pharmaceuticals/2459392/
- Merz Pharma Group Acquires Anteis S.A.https://practicaldermatology.com/news/20131112-merz_pharma_group_acquires_anteis_sa/2459418/
- Dr. Alexa Kimball Highlights Early Response, HiSCR75 Findings With Tulisokibart in Hidradenitis Suppurativahttps://practicaldermatology.com/news/dr-alexa-kimball-highlights-early-response-hiscr75-findings-with-tulisokibart-in-hidradenitis-suppurativa/2488609/New Phase 2b data for tulisokibart may provide early clinical evidence supporting tumor necrosis factor-like cytokine 1A (TL1A) as a therapeutic target in hidradenitis suppurativa (HS), according to study investigator Alexa Kimball, MD, MPH.
- Science of Skin Summit: AI in Medicine Requires More Than Knowing Which Model Scores Besthttps://practicaldermatology.com/news/science-of-skin-summit-ai-in-medicine-requires-more-than-knowing-which-model-scores-best/2488531/Artificial intelligence models are evolving so rapidly that clinicians may struggle to determine which tools they can trust, but choosing the model that performs best on a standardized test may not provide the answer. Speaking at the Science of Skin Summit, Roxana Daneshjou, MD, PhD, discu
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th